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Abstract
Background: Cells of the oligodendrocyte (OL) lineage play a vital role in the production and maintenance of myelin, a
multilamellar membrane which allows for saltatory conduction along axons. These cells may provide immense therapeutic
potential for lost sensory and motor function in demyelinating conditions, such as spinal cord injury, multiple sclerosis, and
transverse myelitis. However, the molecular mechanisms controlling OL differentiation are largely unknown. MicroRNAs
(miRNAs) are considered the ‘‘micromanagers’’ of gene expression with suggestive roles in cellular differentiation and
maintenance. Although unique patterns of miRNA expression in various cell lineages have been characterized, this is the
first report documenting their expression during oligodendrocyte maturation from human embryonic stem (hES) cells. Here,
we performed a global miRNA analysis to reveal and identify characteristic patterns in the multiple stages leading to OL
maturation from hES cells including those targeting factors involved in myelin production.
Methodology/Principal Findings: We isolated cells from 8 stages of OL differentiation. Total RNA was subjected to miRNA
profiling and validations preformed using real-time qRT-PCR. A comparison of miRNAs from our cultured OLs and OL
progenitors showed significant similarities with published results from equivalent cells found in the rat and mouse central
nervous system. Principal component analysis revealed four main clusters of miRNA expression corresponding to early, mid,
and late progenitors, and mature OLs. These results were supported by correlation analyses between adjacent stages.
Interestingly, the highest differentially-expressed miRNAs demonstrated a similar pattern of expression throughout all
stages of differentiation, suggesting that they potentially regulate a common target or set of targets in this process. The
predicted targets of these miRNAs include those with known or suspected roles in oligodendrocyte development and
myelination including C11Orf9, CLDN11, MYTL1, MBOP, MPZL2, and DDR1.
Conclusions/Significance: We demonstrate miRNA profiles during distinct stages in oligodendroglial differentiation that
may provide key markers of OL maturation. Our results reveal pronounced trends in miRNA expression and their potential
mRNA target interactions that could provide valuable insight into the molecular mechanisms of differentiation.
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Introduction
Oligodendrocytes (OLs) play a critical role within the central
nervous system (CNS) by producing the insulating protein myelin,
which provides efficient neuronal conductivity by decreasing ion
leakage and capacitance of axonal membranes. Significant damage
to OLs results in demyelination and hinders effective communica-
tion among neurons. Correspondingly, CNS demyelinating condi-
tions, such as spinal cord injury, multiple sclerosis, transverse
myelitis, and optic neuritis can result in severe motor, sensory, and
cognitive impairment [1,2]. Cellular replacement strategies involv-
ing the transplantation of cells from the oligodendrocyte lineage to
induce remyelination have been utilized in various studies [3,4,5,6].
One of the most promising sources for this cell therapy is human
embryonic stem (ES) cells, which are capable of unlimited
proliferation and differentiation into cell types from all three germ
layers. As such, human ES cell-derived approaches for producing
oligodendrocyte cells offer significant potential for these therapeutic
efforts. The utility of hES-derived OL progenitors (OPCs) have
been shown in animal models of multiple sclerosis and spinal cord
injury [3,6,7,8]. However, little is known about the fundamental
regulatory mechanisms that control the differentiation of human ES
cells into OLs and only a handful of laboratories have demonstrated
the ability to derive mature OLs [6,9]. The difficulty in deriving
these cells is due in part to the lack of knowledge regarding the
regulators of oligodendrocyte development.
MicroRNAs (miRNAs) are ,23 nucleotide molecules that have
been termed the ‘‘micromanagers’’ of gene expression [10]. They
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posttranscriptional level by binding to the mRNA of protein-
coding genes. Specifically, the ‘‘seed’’ region of a miRNA
(centered on nucleotides 2–7) binds to the 39 untranslated region
(UTR) of target mRNAs via Watson-Crick complementary base
pairing. Subsequently, these target mRNAs are most commonly
repressed by undergoing Argonaute-catalyzed cleavage and/or
destabilization [11,12]. MiRNAs are known to play important
roles in many cellular processes [13,14,15], including stem cell
maintenance [16] and differentiation including those of the neural
lineage [17,18]. However, only a few laboratories have investi-
gated the specific miRNA expression in murine oligodendrocytes
[19,20,21] and no study to date has characterized miRNA
expression in human OLs. This information is critical since
miRNAs are potential key regulators of differentiation, as
demonstrated by their dynamic expression throughout develop-
ment. In fact, miRNA deficient mice with Dicer deletions were
shown to display significant impairment in oligodendrocyte
differentiation and production of myelin genes [22,23].
Using a human ES cell derived model of OL differentiation, we
have shown that miRNAs are temporally regulated during this
process by studying neural embryoid body (EB) cells, neural
progenitor (NP) cells, glial-restricted precursor (GP) cells,
oligodendrocyte precursor (OP) cells, and OLs. Additionally, this
analysis reveals a pronounced relationship between the highest
differentially expressed miRNAs at a particular stage and their
corresponding grouped expression over the course of oligoden-
drocyte differentiation. These results suggest the possibility that
they share common targets. Moreover, a number of these miRNAs
have putative targets in proteins with known or suspected roles in
myelination. Thus, the following study is the first report
performing a thorough characterization of global miRNA
expression levels encompassing the complete differentiation
scheme from hES cells to terminally differentiated OLs.
Results
Embryonic stem cell differentiation into oligodendrocyte
lineage cells
The differentiation of human ES cells into OL lineage cells has
been previously demonstrated by a handful of laboratories.
Recently, our group has implemented a modified differentiation
protocol demonstrating increased purity and efficiency [24], with
.95% of cells expressing appropriate markers at defined cell
stages. Specific stages were defined in culture by changes in growth
factors, substrate adherence conditions, morphology (Figure 1a–
c), and gene expression of known markers (Figure 1d–i). Neural
differentiation was initiated by EB formation as commonly used to
generate early neuroectodermal cells transitioning from undiffer-
entiated ES cells. In suspension, these cells begin to lose expression
of key markers of pluripotency such as OCT4 and NANOG and
begin to express SOX1, PAX6, and NESTIN. Once plated these
cells begin a flattened morphology and divide as a monolayer in
the dish. These cells continue to express early neural markers but
also begin to express A2B5 and Sox10. For the purpose of this
study, these cells represent early to late neural progenitor
formation, respectively. Glial progenitors produce a bipolar
morphology and begin to express Olig1, PDGFRa and NG2.
Upon further culture and the addition of PDGF-AA, GPs begin to
exhibit multiple filopodial extensions and they begin to express O4
and later express O1, GalC and CNPase markers
[25,26,27,28,29,30,31]. These OP cells were evaluated over time
which we define as early, mid- and late OP cells. Specifically, cells
at the early OP stage began to express O4, while cells of the mid
OP stage expressed O1 and GalC, and the late OP stage expressed
CNPase. Although these are commonly known as markers of
mature oligodendrocytes, these cells did not express myelin basic
protein (MBP). Moreover, these cells continued to proliferate in
culture, indicative of a progenitor-like state. The production of
MBP after the addition of T3 and withdrawal of growth factors
corresponded with their maturation into OLs. This was consistent
with changes in their morphology with large cell bodies and
extensive filopodial branching.
MiRNA Profiles
Among the 866 miRNAs present on the array chip, 183
miRNAs were detected over eight stages of oligodendrocyte
differentiation. The heat map in Figure 2 shows the detected
miRNAs displaying highest variance (top 30th percentile)
throughout differentiation. From these miRNAs, two general
bimodal patterns were observed across the eight stages. The
expression of all detected miRNAs with greater than 2-fold
expression between the eight stages is displayed in Table S1. The
key miRNAs discussed in this manuscript were validated by
conducting real-time qRT-PCR for samples from the appropriate
stages, including the following: miR-199a and miR-145 at the
OP1, OP2, OP3, and OL stages; miR-214 at the OP1 and OP2
stages; miR-184 and miR-1183 at the GP and OP1 stages
(Table 1). The relative expression measured for these miRNAs
show consistency with microarray results.
Using correlation analysis, we compared the overall miRNA
expression profiles by studying the closest and furthest time points
of differentiation (EB and OL, respectively). As expected, the
overall miRNA expression levels of undifferentiated ES showed
significantly lower correlations with differentiated OLs than EBs.
Linear regression plots (Figure 3) of undifferentiated ES cells
demonstrated much higher correlation to the EB stage (r=0.91)
than to the OL sage (r=0.70). Another study demonstrated
similar trends in ESCs, EBs and terminally differentiated cells
during endothelial cell differentiation [32]. Our results demon-
strate the importance of studying the lineage development of a
cell type from ES cells versus just an undifferentiated and mature,
or ‘‘very differentiated’’ state. For example, the cluster of miR-
512-3p, miR-205, and the miR-302 family illustrated on the heat
map demonstrates high expression in undifferentiated ES and
early neural progenitor stages, downregulation during the glial
restricted and early OP transitions, but then additional high
expression during mid to late OP development. One possible
explanation for this kind of expression patterning is that the
miRNAs regulate different targets at different stages of OL
development. Another is the result of targeting proteins with
pleiotropic effects in different niches. Thus, our report empha-
sizes the complexity of studying miRNAs during differentiation
by showing how certain miRNAs may have unrelated roles at
various stages of lineage development. Principal component
analysis (PCA) was conducted to detect overall variation between
the different groups (Figure 4), which produced four main
clusters among the differentiating cells: (1) early neural progen-
itors (2) early glial progenitors (GP and OL1 stages), (3)
developing oligodendrocyte progenitors (OP2 and OP3 stages),
and (4) mature oligodendrocytes (OL stage).
MiRNAs demonstrating the highest differential
expression at each stage-specific transition
Our results show dynamic trends in miRNA expression during
OL differentiation strongly suggesting, as it has in other systems,
that miRNAs play an important role in regulating differentiation.
Specifically, miRNAs which display significant changes at stage-
Oligodendroglial Cell miRNAs
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process [10]. Thus, we focused our attention to miRNAs which
demonstrated the greatest positive and negative fold changes at
each stage transition. Figure 5 summarizes the top ten increasing
and decreasing miRNAs at early stage transitions of oligodendro-
cyte differentiation. At the ESC-EB stage transition, the top 10
miRNAs showing the greatest reduction in expression experienced
a ,3.8-fold change in expression. Similarly, the EB-NP stage
transition showed modest downregulation, with a maximum ,2.8-
fold repression. Conversely, the top differentially upregulated
miRNAs at these two stage transitions showed much greater
changes, with a maximum ,14-fold change at the ESC-EB
transition and a maximum ,6.8-fold change at the EB-NP
transition.
Similar information is presented for early glial progenitor stage
transitions (NP to GP, GP to OP1) (Figure 6), developing
oligodendrocyte precursor stage transitions (OP1 to OP2, OP2 to
OP3) (Figure 7), and transition into the late oligodendrocyte
stage (OP3 to OL) (Figure 8). The NP-GP transition showed
steep negative differential expression with a maximum ,24-fold
change and high upregulation with a maximum ,9.7-fold
change. The transition from GP to OP1 was less pronounced
in terms of both a maximum ,5.2-fold downregulation and a
maximum ,3.6-fold upregulation. The most significant changes
were seen at the OP1 to OP2 transition and at the OP3 to OL
transition. The former stage showed a maximum ,41-fold
downregulation and maximum ,6.4-fold upregulation, while the
latter stage contained a maximum ,32-fold positive change and
a maximum ,170-fold negative change. The OP2 and OP3
stages showed the least amount of change in miRNA expression,
with a maximum ,2.0-fold downregulation and ,3.7-fold
upregulation. The corresponding graphs within these figures plot
the temporal expression of each of these differentially expressed
miRNAs from the pluripotent ES stage to the differentiated OL
stage. Unique trends within the accompanying plots show
that groups of miRNAs with the highest fold changes at a given
transition display a similar expression pattern during
differentiation.
Figure 1. Morphological development and indirect immunofluorescence detection of key markers of OLs in culture. (a) Neural EBs
derived from hES cells. (b) Immature OPCs derived from hES cells demonstrate bipolar morphology, (c) while later progenitors develop multiple
oligodendrocytic projections. (d) Pax6 (green) in cryosectioned EBs after 15 days, (e) A2B5 positive sorted NPs expressing nestin (green), (f) Olig1 (red)
expressing GPs, (g) O4+ (red) OP cells, and (h) MBP (green) expressing OLs which also express (i) C11orf9 (human homolog to MRF) red nuclei and
Olig1 (green). Dapi (blue) stain nuclei. Scale bars: 100 um.
doi:10.1371/journal.pone.0010480.g001
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differentially expressed miRNAs
In addition to studying overall patterns of miRNA expression
throughout oligodendrocyte differentiation, we identified several
myelin-associated genes that have high target bias to the top
differentially expressed miRNAs reported above (Table 2). These
include chromosome 11 open reading frame 9 (C11orf9), myelin
gene regulatory factor (Mrf), claudin-11 (Cldn11), myelin
transcription factor 1-like (Mytl1), myelin-associated oligoden-
drocyte basic protein (Mobp), myelin protein zero-like 2 (Mpzl2),
and discoidin domain receptor tyrosine kinase 1 (Ddr1). These
target predictions were made by detecting miRNAs with
significant expression changes at each step of differentiation
between GPs and OLs.
From our top ten differentially expressed miRNAs at the early
OP to mid OP stage transition, two miRNAs (miR-199a-5p and
miR-145) show strong target bias towards C11Orf9. This gene is
speculated to be the human analog to the mouse MRF, a protein
which has been shown to be critical for oligodendrocyte
maturation and myelin production [33]. MiR-199a-5p has three
sites with evolutionarily conserved 8mer seed matches to the 39
UTR of C11Orf9, suggesting a high probability for miRNA-
mRNA interactions. Importantly, miR-199a-5p showed a sharp
,8.6-fold decrease in expression from the early OP to mid OP
stage, followed by minimal ,1.1-fold change during the mid OP
to late OP stage transition. Then, miR-199a-5p levels rose (,1.7
fold) at the final stage of differentiation. This miRNA expression
pattern is in accordance with published MRF expression results,
potentially suggesting that changes in miR-199a-5p expression
may be concomitant with the initiation of MBP expression.
However, while the increase of miR-199a-5p at the final stage
corresponds with the decreased MRF expression at this transition,
additional validation is necessary. In addition, miR-145 also
followed a similar expression pattern increasing during the first
transition from OP1 to OP2, stable during OP2 to OP3 and then
subsequently increasing from OP3 to OL. MiR-199a-5p, with a
,8.6-fold decrease from OP1 to OP2 stage, contains four total
evolutionarily conserved target sites (three 8mer, one 7mer-1A)
within the 39 UTR of DDR1 mRNA. Like MRF, DDR1 has been
shown to be upregulated during oligodendrocyte differentiation
and remyelination [34]. MiR-214 also shows a ,34-fold decrease
from the OP1 to OP2 transition and has a strong evolutionarily
conserved 8mer target site to Mobp, which is important for
providing the proper structural properties of myelin. Additionally,
miR-205 showed a ,9.2-fold downregulation during the OP3 to
OL transition, which contains a conserved 8mer complementary
site within the Cldn11 39-UTR. This gene is expressed in
oligodendrocytes, encoding for a transmembrane protein involved
in interactions at tight junctions, and is the third most abundant
protein in CNS myelin [35].
As GPs have the potential to derive both OLs and astrocytes, we
studied targets that not only facilitate OP fate but also those that
may inhibit astrocyte differentiation. By comparing GPs and OPs,
we identified several miRNAs that inhibit targets that facilitate
astrocyte differentiation. The highest upregulated miRNA (miR-
184) at the GP-early OP transition shows a strong conserved 8mer
Figure 2. Hiereracheal clustering of top differentially ex-
pressed miRNAs. From the 183 detected miRNAs, those with variance
in the top 30
th percentile across OL differentiation were selected for
cluster analysis. Two prominent bimodal distributions resulted from this
dataset.
doi:10.1371/journal.pone.0010480.g002
Table 1. Validation of key miRNAs.
qPCR microarray
FC mean FC SE p-value FC mean FC SE p-value
miR-199a-5p
OP1–OP2 212.662 0.009 4.57E-04 23.109 0.624 1.26E-01
OP2–OP3 21.066 0.847 4.27E-01 20.077 0.037 2.83E-01
OP3 - OL 13.959 1.893 8.58E-02 0.783 0.623 4.27E-01
miR-145
OP1–OP2 29.038 0.142 1.00E-02 22.869 0.460 1.01E-01
OP2–OP3 0.239 0.121 2.98E-01 0.106 0.018 1.11E-01
OP3 - OL 8.381 2.511 1.85E-01 0.661 0.292 2.64E-01
miR-214
OP1–OP2 210.477 0.167 1.01E-02 25.100 0.268 3.34E-02
miR-184
GP - OP1 6.485 0.102 1.00E-02 1.864 0.174 5.94E-02
miR-1183
GP - OP1 1.677 0.173 6.54E-02 2.130 - -
Real-time qRT-PCR validation of microarray data for key miRNAs discussed in
the text at appropriate stage transitions. Fold change means (log2), standard
errors and p-values are listed for the two biological replications.
doi:10.1371/journal.pone.0010480.t001
Oligodendroglial Cell miRNAs
PLoS ONE | www.plosone.org 4 May 2010 | Volume 5 | Issue 5 | e10480binding site to BCL2-like 1 (Bcl2l1), a gene highly expressed in
astrocytes [36]. MiR-1183 was also found to contain a stringent
conserved binding site to the mRNA 39 UTR of eukaryotic
translation initiation factor 2B, subunit 5 epsilon (Eif2b5), which
has been shown to facilitate astrocyte differentiation [37].
Discussion
MiRNA expression profiling utilizing microarrays is a widely
utilized procedure for the discovery of miRNA-mRNA interac-
tions that regulate cellular processes. Most studies employ
expression profiling as a starting point for identifying highly
differentially expressed miRNAs that regulate a protein of interest.
Since these studies focus on characterizing miRNA-mediated
protein regulation at a particular stage transition, miRNA
expression information is typically confined to narrow time
frames. The overall goal of this study was to characterize the
miRNA signature of several distinct stages that are essential for
OL generation.
Interestingly, we discovered that miRNAs sharing the highest
fold changes at a given transition demonstrated similar expression
patterns over time. One potential explanation for this observation
alludes to the more recent miRNA-mRNA interaction model
proposed by Bartel and Chen [10,11], in which miRNA induction
can be thought of as a combinatorial rheostat that fine-tunes
protein levels rather than acting solely as a classical binary off-
switch. In this model, the 39-UTR of one target mRNA molecule
may contain several sites where different miRNAs may bind. The
effective repression is then partly a function of the number of
different miRNAs that bind to a particular 39-UTR. It is possible
that some of the miRNAs demonstrating similar temporal
expression patterns in Figure 5, Figure 6, Figure 7 and Figure 8
may be co-regulating a shared set of mRNA targets. For instance,
miR-145 and miR-199a-5p within our data showed similar
expression patterns throughout differentiation and both contain
conserved 8mer predicted seed pairings to multiple sites within the
39-UTR of C11orf9. Thus, both miRNAs may co-regulate C11orf9
through multiple sites within the same UTR and stoichiometrically
affect gene expression by the number of sites they bind. This has
been proposed to explain the graded versus binary effects of
regulation observed in some miRNA interactions [11]. Another
potential explanation for these trends is that groups of miRNAs
regulate different proteins within common pathways. For instance,
a study analyzing miRNA expression profiles of ovarian
adenocarcinomas demonstrated that two similarly expressed
miRNAs (miR-9 and miR-223) regulate two independent targets
of a common pathway involved in ovarian metastatis [38].
Nonetheless, further investigations will be required to determine
Figure 3. MiRNA correlation between stages. Correlation of miRNA expression levels (log2) between the ES, EB, NP, GP, OP1, OP2, OP3, and OL
stages. Samples at each stage transition as well as the first (ES) and last (OL) stages of differentiation were compared. From the seven adjacent stage
transitions, the OP2 to OP3 stages displayed the highest correlation (r=0.98), while the OP1 to OP2 stages showed the least correlation (r=0.65).
doi:10.1371/journal.pone.0010480.g003
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cyte differentiation.
Although no comparable investigations have been performed on
human cells, some interesting parallels were detected between
miRNAs found in this study and those reported in mouse and rat
OL cell types. A study by Lau, et al. [20] explored the relative
abundance of miRNAs within isolated rat CNS OP cells, CNS
OLs, and PNS Schwann cells. We compared our data of GP and
OP stages corresponding to A2B5+ GalC2 and A2B52 GalC+
cell types from this study. From the top twenty miRNAs showing
highest expression in A2B5+ GalC2 cells, miR-130a, miR-16,
miR-17, and miR-20a were also in the top twenty expressed
miRNAs from our GPs. Similarly, miR-17, miR-20a, miR-21,
miR-16, miR-103, and miR-107 identified in A2B5-GalC+ cells
showed overlapping expression with our OPs. It is intuitive that
the most highly expressed miRNAs at these stages may be
potentially repressing the expression of astrocyte proteins.
Interestingly, miR-16 was found to have an evolutionarily
conserved 8mer target site with a high prediction score to GFAP,
one of the most widely used markers for characterizing astrocytes.
This same miRNA was also found to have a target bias for
excitatory amino acid transporter 2 (Eaat2), which is upregulated
in astrocyte progenitors [39]. Additionally, miR-17 and miR-20a
were predicted to target membrane associated guanylate kinase,
WW and PDZ domain containing 3 (MagI-3), a junctional
protein found in astrocytes [40]. Finally, miR-21 was found to
contain a strong target bias towards Fas ligand (Faslg), which is
co-expressed with GFAP in astrocytes [41]. Another report
demonstrates that miR-23 facilitates OL development by nega-
tively regulating lamin B1 (LMNB1), a protein found to repress
production of MBP, proteolipid protein 1 (PLP), and myelin
oligodendrocyte glycoprotein (MOG) [19]. Expression data from
our microarray results show high levels of miR-23a throughout the
GP to OL stages. MiR-23b was also present in high levels during
these same stages, although with reduced expression at the OP2
and OP3 stages.
In addition to miRNAs that have been previously reported, we
also evaluated the predicted targets of the most differentially
expressed miRNAs in our data with known or putative associations
with oligodendrocyte differentiation and myelin production. One
interesting predicted target is C11Orf9, which shows 80%
homology to myelin gene regulatory factor (MRF) found in mice
[33]. MRF is a recently discovered transcriptional regulator that is
required for CNS myelination. RNAi knockdown experiments of
MRF in cultured oligodendrocytic cells were found to prevent
expression of many important CNS myelin genes, including
CNPase, PLP, MAG, and MOBP. Conversely, overexpression of
MRF within OP cells promoted myelin-associated gene expres-
sion. Mice without MRF could only generate premyelinating
oligodendrocytes, which lacked myelin gene expression and failed
to myelinate axons, eventually dying during the third postnatal
week from severe neurological abnormalities. Under standard
developmental conditions, MRF expression levels are low in early
OP cells and significantly increase with OP cell maturation. As
these cells mature into MOG+ OLs, MRF levels begin to decrease.
Since miRNAs act by repressing gene expression, those targeting
MRF would show inverse expression to the above trend. We
tested, for the first time in human OLs, the expression of the
human homolog to MRF, C11Orf9, which was detected at high
levels in our immunofluorescence data. Target predictions for
miR-199a-5p showed high likelihood for C11Orf9 repressive
interactions. Interestingly, miR-199a-5p demonstrated a large
decrease in expression beginning at the early OP stage and an
increase at the final stage. This would suggest a significant release
of miRNA-mediated C11Orf9 repression through OP cell differ-
entiation, followed by a slight increase in repression at the terminal
stage transition, in agreement with published mouse MRF results.
Similarly, the expression pattern of miR-145 at these stages
conformed to the same trend as miR-199a-5p. Therefore, these
data suggest that miR-199a-5p and miR-145 may be simulta-
neously regulating the human homolog of MRF.
Besides having a strong target bias for C11Orf9, miR-199a-5p
also has a significant bias for targetting DDR1, a tyrosine kinase
receptor found to be upregulated during in vivo remyelination and
in vitro oligodendrocyte differentiation [34]. The highly differen-
tial expression of miR-199a-5p, along with its high number of
stringent evolutionarily conserved target sites to DDR1 mRNA,
suggests a likely regulatory interaction involved in oligodendro-
cyte differentiation. In a similar fashion, another highly
differentially expressed miRNA (miR-214) which displays a
highly complementary alignment within the 39 UTR of MOBP
mRNA demonstrates a decrease in OP cells then a sharp increase
in OLs. MOBP is abundantly produced within the cytoplasm of
OP cells and later localized to the processes of mature OLs,
containing clusters of positively charged amino acid residues
necessary for myelin compaction [42]. Upon demyelination,
electron microscopy studies have shown that mice lacking MOBP
had problems compacting newly produced myelin suggesting that
it is necessary for the proper structure and function of myelinated
axons.
During the final stage transition, miR-205 showed significant
downregulation. This miRNA shows a strong target bias for the
39-UTR mRNA of CLDN11, a tight junction protein which has
been shown to increase in expression as oligodendrocyte
progenitors develop into mature oligodendrocytes [35]. As such,
Figure 4. PCA analysis of OL differentiation. Principal compo-
nents 1, 2, and 3 in 3D space, representing approximately 70% of the
variation. Four main clusters were observed among the differentiating
cells, including: (1) early neural progenitors (red), early glial progenitors
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increased expression of Cldn11 at this stage. Several other
differentially expressed miRNAs at this final stage transition
may have important roles in the terminal differentiation of
oligodendrocytes. From the top ten downregulated miRNAs at
this transition, six miRNAs (miR-367, miR-302a, miR-302c,
miR-372, miR-302b, and miR-302d) have been shown to
encourage proliferation and are highly expressed in undifferen-
tiated cells and cancer stem cells [43,44,45,46,47,48]. This
suggests that their decreased expression between the OP3 to OL
stage may be associated with the inhibition of proliferation and
the promotion of maturation in developing oligodendrocytes. On
the other hand, the top upregulated miRNAs at the OP3-OL
transition included miRNAs (miR-181a, miR-181b, miR-125b,
and miR-184) that are associated with decreased proliferation in
maturing CNS cells and decreased malignancy in glioma stem
cells [49,50,51,52,53,54,55]. Thus, their increased expression
suggests potential roles in OL maturation and normal oligoden-
dritic development.
Conversely, another study demonstrated that the absence of
miR-206 was essential for OL differentiation from rat bipotential
oligodendrocyte-type 2-astrocyte (O-2A) progenitor cells which
have the capability of generating both oligodendrocytes and
astrocytes by targeting the tubilin polymerization-promoting
protein (TPPP/p25), a marker of myelinating oligodendrocytes
[21]. Our results also demonstrate a progressive decrease in miR-
206 during ESC-derived OL differentiation. However, our data
show a significant increase in this miRNA during the OP3-OL
transition. There are several possible explanations for this
increase. For instance, TPPP/p25 is a potential target for several
miRNAs, including miR-1. Thus, an increase in one miRNA
such as miR-206 may not be sufficient to significantly repress the
expression of this protein. This is consistent with our results that
suggest groups of miRNAs rather than a single miRNA may
potentially regulate a common target. It is also not known
whether these results are due to differences in rat and human, or
whether the absence of miRNA-206 is only required for the
initiation of the TPPP/p25 pathway prior to myelination.
Similarly, recent rodent studies demonstrated the roles of miR-
219[56,57] and miR-338[57] in controlling oligodendrocyte
differentiation. While our data showed many similarities between
previous rodent studies, these two miRNAs were not detected in
our human OP cells and OLs, signifying the importance of
studying oligodendrocytes derived from human cells in addition
to animal models.
Finally, we identified miRNAs with potential roles in
preventing astrocytic differentiation at the point of astrocyte-
oligodendrocyte lineage divergence (GP to early OP transition).
The highest upregulated miRNA at this transition, miR-184,
shows a high likelihood of binding to Bcl2l1, a gene which has
been shown to be co-expressed with GFAP in various samples of
astrocyte tissue [36]. In this study, BCL2L1 protein levels were
found to be much higher than GFAP, suggesting a potentially
strong role for this gene in astrocytes. Additionally, another
positive differentially expressed miRNA at the GP-early OP
transition, miR-1183, generated a high prediction score to an
Figure 5. Top differentially expressed miRNAs at early neural progenitor stage transitions. Fold change values (log2) and expression
profiles of the top ten downregulated miRNAs at the (a) ES-EB and (b) EB-NP stage transitions and the top ten corresponding upregulated miRNAs at
the (c) ES-EB and (d) EB-NP stage transitions.
doi:10.1371/journal.pone.0010480.g005
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tions in this gene have been associated with vanishing white
matter disease [37]. While this leukodystrophy results in
demyelination, GPs cultured with this mutation were able to
produce normal OLs in culture. However, GPs with a mutation
in Eif2b5 produced very few numbers of GFAP+ astrocytes.
Furthermore, Eif2b5 RNAi studies also showed significantly
decreased production of GFAP+ astrocytes from human fetal
GPs. Therefore, it is possible that transfection of miR-184 and/or
miR-1183 analogs to GPs may help reduce astrocyte differenti-
ation and promote the production of oligodendrocyte cultures
with increased purity.
In summary, we have shown that our analyses of miRNA
profiling can be used to distinguish between different stages of
oligodendrocyte differentiation. Specifically, we have identified a
number of miRNAs which may potentially regulate or mark key
steps in OL differentiation from human ES cells, along with their
potential protein targets. These interactions may have significant
roles in oligodendrocyte differentiation and myelin production.
Materials and Methods
Cell culture
H1 (WA01) purchased from WiCell (Madison, WI) and
expanded in ESC growth media
1 and differentiated according to
modified published protocols
2 into embryoid bodies (EBs), neural
progenitors (NPs), glial restricted precursors (GPs), oligodendro-
cyte precursors (OPs), and finally premyelinating oligodendrocytes
(OLs). Neural differentiation of ESCs were initiated via embryoid
body (EB) suspensions with B27 medium [58] supplemented with
200 ng/ml noggin, 20 ng/ml FGF2, and 20 ng/ml FGF4 (all
from R&D Systems). EBs (or early neural progenitors) were grown
for 15 days and then plated on matrigel and grown in B27 media
supplemented with 20 ng/ml FGF2 for 5 days producing late
neural progenitors (NPs), which were identified by A2B5
expression. Neural progenitors were isolated by magnetic-
activated cell sorting (MACs) by A2B5 which produced .99%
A2B5+ and Nestin+ cells.
Populations of glial progenitors (GPs) which are capable of
generating both astrocytes and oligodendrocytes were distin-
guished from neural progenitor cultures by their expression of
PDGFRa and Olig1, and distinguished from more differentiated
OP cells by their lack of expression of O1 and O4. Cultures
containing GP cells were then split onto matrigel with 0.05%
trypsin/EDTA and further differentiated into oligodendrocyte
progenitors in B27 media with the addition of 20 ng/ml of PDGF
(PeproTech) and 20 ng/ml EGF (R&D Systems) for 25 days, first
expressing O4 (pre-oligodendrocytic progenitors) and later ex-
pressing O1, GalC and CNPase markers (pro-oligodendrocytic
progenitors) Terminal differentiation into mature OLs was
induced in B27 supplemented with 40 ng/ml 3,395-Triido-L-
thyronine (T3) for an additional three weeks. Mature OLs were
distinguished from OP cells by their expression of myelin basic
protein. After the addition of the appropriate factors, GPs, OPs
and OLs were isolated for analysis. For each stage, cell purity was
based on ICC, as performed previously [24]. These studies showed
Figure 6. Top differentially expressed miRNAs at early glial precursor stage transitions. Fold change values (log2) and expression profiles
of the top ten downregulated miRNAs at the (a) NP-GP and (b) GP-OP1 stage transitions and the top ten corresponding upregulated miRNAs at the
(c) NP-GP and (d) GP-OP1 stage transitions.
doi:10.1371/journal.pone.0010480.g006
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Importantly, OLs and not OPCs expressed MBP.
Immunofluorescence
Immunostaining was performed on tissue and on cells using
anti-Oligodendrocyte Specific Protein (CLDNanti-Oligodendro-
cyte marker 1 (O1, 1:20, Millipore) mouse anti-Oligodendrocyte
marker 4 (O4, 1:20, Millipore), rabbit anti-galactocerebroside
(GalC, 1:20, Millipore), anti-A2B5 (1:20, Millipore), mouse anti-
nestin (1:20, Millipore), rabbit anti-Pax6 (1:20, Abcam), rabbit
anti-NG2 (1:20, Millipore), goat anti-Sox10 (1:20, Santa Cruz),
rabbit anti-PDGFRa (1:20, Abcam), mouse anti-Olig1 (1:20,
Millipore), rat anti-MBP (1:20, Abcam) and mouse anti-CNPase
(1:20, Millipore) using standard protocols along with fluorescent
secondary antibodies (Millipore). DAPI was used to stain nuclei to
determine the percentage of immunopositive cells.
miRNA isolation
Eight total populations were isolated for miRNA analyses.
These included undifferentiated ES cells, EB cells, NP cells, GP
cells, OP cells (Day 7, Day 14, Day 25), and OL cells. MiRNA was
isolated from ,2610
5 cells using miRNeasy Mini kits (Qiagen)
followed by quality checks of both total RNA and small RNA
using a 2100 Bioanalyzer and software which detected 28S and
18S ribosomal RNA ratios, generated a RNA Integrity Number
(RIN), concentration of sample, and ribosomal ratio. Only samples
with 28S/18S.1.2, RIN.8 and detectable miRNA were used for
the study.
miRNA microarray
Human miRNA Microarray V3 kits (G4470C, Agilent Technol-
ogies) were employed for this study following manufacturer’s
protocols. The Agilent miRNArrays contain probes for all 866
human and 89 human viral miRNAs reported from the Sanger
database v12.0 (http://microrna.sanger.ac.uk/sequences/). Each
miRNA species is printed 20 times with replicate probes on the
array. 100 ng of total RNA was dephosphorylated with11.2 units of
calf intestine alkaline phosphatase at 37uC for 30 minutes and
followed by end-labeling with pCp-Cy3 (Agilent Technologies) and
15 units of T4 RNA ligase (GE Healthcare) at 16uC for 2 hours.
Labeled samples were purified with Micro Bio-Spin 6 columns (Bio-
Rad). Labeling efficiency and nucleic acid concentration was
measured using Nanodrop 1000. Samples were mixed with 10x
blocking agent and 2x Hi-RPM hybridization buffer (Agilent
Technologies) and microarray hybridization was carried out at
55uC with rotation at 20 rpm in a designated Agilent G2545A
hybridization oven for 20 hours. Microarrays were washed and
scanned using an Agilent Scanner controlled by Agilent Scan
Control 7.0 software. Hybridization images were scanned
with Agilent Feature Extraction 9.5.3.1 software for miRNA
microarray. Microarray analysis was performed for two biological
replicates.
RT-PCR validation
Quantitation of miRNAs was carried out using TaqManH
microRNA Assays (Applied Biosystems). Briefly, 3.34 ng of
template total RNA was reverse-transcribed in a 5 mL reaction
Figure 7. Top differentially expressed miRNAs at developing oligodendrocyte precursor stage transitions. Fold change values (log2)
and expression profiles of the top ten downregulated miRNAs at the (a) OP1–OP2 and (b) OP2–OP3 stage transitions and the top ten corresponding
upregulated miRNAs at the (c) OP1–OP2 and (d) OP2–OP3 stage transitions.
doi:10.1371/journal.pone.0010480.g007
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miRNA-specific stem-loop primers for candidate miRNA (Applied
Biosystems). The reverse transcription reaction was diluted by
adding 32.3 mLH 2O, then 2.25 mL of the diluted mixture was
introduced into a 5 mL PCR reaction using TaqManH Universal
PCR master mix without AmpErase UNG. Real-time PCR was
performed using an Applied Biosystems 7900HT Thermocycler at
95uC for 10 min, followed by 40 cycles of 95uC for 15 sec and
60uC for 1 min. Real-time qRT-PCR was performed for two
biological replicates with technical triplicates. The 18S rRNA was
used as the housekeeping gene.
miRNA analysis
After hybridization images were digitized using Agilent Feature
Extraction 9.5.3.1 software, the average background intensity was
computed and subtracted from each digitized raw intensity value.
The software then computed the total error for each background-
subtracted value. Detectable miRNAs were defined as those
containing expression levels greater than three times the computed
error for at least one stage. Detected background-subtracted data
were converted to log2 values. The microarray data reported in
this manuscript is described in accordance with MIAME
guidelines. Quantile normalization was performed to account for
differences in microarray input between samples. Pearson
correlation coefficients were calculated for miRNA expression
levels between each subsequent stage of oligodendrocyte differen-
tiation. Fold changes at each of the seven stage transitions were
computed for each miRNA and the greatest positive and negative
results were ranked. Paired two-sample t-tests were carried for
each of the top differentially expressed miRNAs at each stage
transition. Corresponding p-values were derived from the
theoretical t-distributions. The above data processing was carried
out with custom algorithms scripted within MATLAB (Math-
works, Natick, MA). Filtering was utilized to select the miRNAs
displaying the highest 30
th percentile variance throughout the
eight stages of differentiation for cluster analysis. Hierarchal
clustering using an implementation of average linkage and
Euclidean distance metric was performed for these filtered
miRNAs. TIGR MeV (Multiple Experimental Viewer) software
[59] was utilized to create clustergrams as well as principal
component analysis plots of the first three components of
variation.
Figure 8. Top differentially expressed miRNAs at the late oligodendrocyte stage transition. Fold change values (log2) and expression
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Targets of the top differentially expressed miRNAs at GP
through OL stages were identified using several different sources of
publicly-available software as each program uses its own unique
algorithms to measure complementarity. To filter this extensive set
of predicted targets, a custom algorithm was developed within
MATLAB to retrieve prediction data from the TargetScan
database [60] and conduct an automated Entrez Gene database
search to only return proteins with reported roles in myelination
and oligodendrocyte differentiation. This dataset was used as a
basis for a focused literature search from the set of all proteins that
display miRNA target bias. Similar targets were also confirmed
with other prediction software that employ stringent base pairing
and evolutionary conservation, including PicTar (http://pictar.
bio.nyu.edu/) and EMBL (http://www.ebi.ac.uk/embl/).
Supporting Information
Table S1 MiRNAs displaying .1.0 (log2) fold change at the
seven stage transitions studied. Fold changes (6SEM) at each stage
transition of oligodendrocyte differentiation are included.
Found at: doi:10.1371/journal.pone.0010480.s001 (0.04 MB
XLS)
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